J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure
TL;DR: Further evaluation of the screening of high risk groups to detect asymptomatic left ventricular systolic dysfunction with the aim of giving treatment to prevent the development of heart failure is merited.
Journal ArticleDOI
Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony.
Friedrich Fruhwald,Astrid Fahrleitner-Pammer,Rudolf Berger,Francisco Leyva,Nick Freemantle,Erland Erdmann,Daniel Gras,Lukas Kappenberger,Luigi Tavazzi,Jean-Claude Daubert,John G.F. Cleland +10 more
TL;DR: CRT exerts an early and sustained reduction in NT-pro-BNP, which appears to reflect improvements in ventricular function and may be a simple method for monitoring the effects of CRT.
Journal ArticleDOI
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
Christian Torp-Pedersen,Marco Metra,Andrew Charlesworth,Phillip Spark,Mary Ann Lukas,Philip A. Poole-Wilson,Karl Swedberg,John G.F. Cleland,Andrea Di Lenarda,Willem J. Remme,Armin Scherhag +10 more
TL;DR: A high prevalence and incidence of diabetes is found in patients with heart failure over a course of 5 years, and new onset diabetes is more likely to occur during treatment with metoprolol than duringtreatment with carvedilol.
Journal ArticleDOI
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
Lars Gullestad,Lars Gullestad,Thor Ueland,Thor Ueland,John Kjekshus,John Kjekshus,Ståle H. Nymo,Ståle H. Nymo,Johannes Hulthe,Johannes Hulthe,Pieter Muntendam,Aram Adourian,Michael Böhm,Dirk J. van Veldhuisen,Michel Komajda,John G.F. Cleland,John Wikstrand,John J.V. McMurray,Pål Aukrust,Pål Aukrust +19 more
TL;DR: Patients with systolic HF of ischaemic aetiology who have galectin-3 values <19.0 ng/mL may benefit from rosuvastatin treatment, however, the data should be interpreted with caution since the overall results of the CORONA study did not show a significant effect on the primary endpoint.
Journal Article
Relation of arrhythmias and electrolyte abnormalities to survival in patients with severe chronic heart failure.
TL;DR: The most important pretreatment predictor of mortality in patients with chronic congestive heart failure was the frequency of ventricular extrasystoles, followed by echocardiographic fractional shortening, a diagnosis of coronary artery disease, and duration of treadmill exercise.